CHALLENGING THE CONVENTIONAL IN IBD TREATMENT

Overall course objective:

Update healthcare professionals with an interest in inflammatory bowel disease (IBD) on the use of selective granulocyte and monocyte apheresis with Adacolumn® as an adjuvant therapy in its management.

Understand the immunomodulatory mechanism of action of Adacolumn® and its scientific basis in controlling intestinal inflammation, as well as to identify the profiles of patients with IBD (ulcerative colitis and Crohn’s disease) who could benefit most from this treatment, either as monotherapy or in combination.

(To listen to the video in your preferred language, please go to the video/subtitle settings and select the language of your choice)

Welcome and Introduction to the Scientific Conference.
Dr. Luis Menchén – Gregorio Marañón General University Hospita

Real Stories, Shared Experiences: Raising Challenges.
Dr. Cristina Suárez – La Paz University Hospital.
Dr. María Algara – 12 de Octubre University Hospital.

Deciphering IBD: Innate Immunity as a Key Player in Inflammation.
Dr. Luis Menchén – Gregorio Marañón General University Hospital.

Neutrophil at the Epicenter of IBD Treatment.
Dr. Eugeni Domènech – Germans Trias i Pujol University Hospital.

Optimizing IBD Therapies: synergistic effect of Adacolumn.
Dr. Iago Rodriguez-Lago – Galdakao University Hospital.

Real Stories, Shared Experiences: Raising Challenges.
Dr. Cristina Suárez – La Paz University Hospital.
Dr. María Algara – 12 de Octubre University Hospital.

Overcome Challenges: Conclusions and Closing Remarks.
Dr. Luis Menchén – Gregorio Marañón General University Hospital.